pubmed.ncbi.nlm.nih.gov

Primary care prescribing patterns in Ireland after the publication of large hypertension trials - PubMed

Primary care prescribing patterns in Ireland after the publication of large hypertension trials

Zubair Kabir et al. Br J Clin Pharmacol. 2007 Sep.

Abstract

Aims: This study assessed prescribing patterns of antihypertensive therapies (AHT) before and after the publication of the LIFE, ALLHAT and VALUE trials between 2000 and 2005.

Methods: The Irish HSE-PCRS prescribing database was used to identify those initiated any AHT. Any change 12 months before and after the trial publications was examined using a segmented regression analysis.

Results: There was little or no effect of any of the trials on new AHT prescribing, except for ALLHAT where there was an increase in new prescriptions for ACE inhibitors, and VALUE with a slight increase in prescriptions for calcium channel blockers.

Conclusions: Our findings show that there was little or no effect of any of the three clinical trials studied on new AHT prescribing patterns in Irish general practice. Future studies should assess any underlying barriers to implementing new evidence into clinical practice.

PubMed Disclaimer

Figures

Figure 1
Figure 1

Relative percentage of each class of anti-hypertensive agents from January 2001 to July 2005: New prescriptions. BB β-adrenoceptor blocking drugs, TZ thiazide-like diuretics, CCB calcium channel blocking drugs, ATEN atenolol, LOSART losartan, VALSART valsartan

Figure 2
Figure 2

The distribution of the number of newly initiated antihypertensive agents over time. % monotherapy (formula image); % dual therapy (formula image); % 3+ therapy (□)

Similar articles

Cited by

References

    1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23. - PubMed
    1. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003. - PubMed
    1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA. 2002;288:2981–97. - PubMed
    1. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–31. - PubMed
    1. Xie F, Petitti DB, Chen W. Prescribing patterns for anti-hypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Report of experience in a Health Maintenance Organization. Am J Hypertens. 2005;18:464–9. - PubMed

Publication types

MeSH terms

Substances